Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101

• Status: Enrolling by invitation
• Trial end date: 2032-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Subjects are enrolled in this study following completion or early discontinuation from a Poseida sponsored or supported study of P-BCMA-101 T cells and will be followed for a total of 15 years post treatment from the last P-BCMA-101 treatment. Subjects will be monitored for safety and efficacy to assess the risk of delayed adverse events (AEs) and assess long-term efficacy, and PK and quantification of P-BCMA-101 T cells. Rimiducid may be administered as indicated.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Poseida Therapeutics, Inc.
• Collaborator: California Institute for Regenerative Medicine (CIRM)

Criteria

Inclusion Criteria:

• Subjects who have received P-BCMA-101 and completed or discontinued early from a Poseida sponsored treatment protocol.

• Subject has provided informed consent.

Exclusion Criteria:

• None